Day two of ASCO 2020 featured late-breaking data from a phase 3 trial evaluating early local therapy in metastatic breast cancer, as well as results of the phase 3 ENDURANCE trial, the ALPHA CAR T-cell trial, and the C-144-01 trial assessing TIL therapy.

Gastrointestinal and breast cancer sessions were featured on the first day of the virtual conference, highlighting practice-changing results from a multitude of studies, including the HER2CLIMB, MINDACT, and PHERGAIN trials.

The 2020 Healthgrades National Health Index compared 100 markets based on a cross-section of factors that contribute to quality care and personal health. Here are the five cities that rise above the rest – did your city make the list?

According to study results presented at ASCO20 Virtual Scientific Program, a year of maintenance therapy with metronomic capecitabine after standard treatment extended DFS among women with operable triple-negative breast cancer.

On May 31, 2020, at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Sessions, late-breaking data dropped for three potentially practice-changing studies: JAVELIN Bladder 100, KEYNOTE-177, and ADAURA.

In this Original Investigation, JAMA Oncology explores the CheckMate 143 Phase 3 trial, asking whether PD-1 immune checkpoint inhibition with nivolumab improves overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma.